How does linerixibat actually stop the itching in primary biliary cholangitis?
Linerixibat blocks the ileal bile acid transporter (IBAT) in your small intestine, preventing bile acids from being reabsorbed back into your bloodstream. Instead, bile acids exit through stool. Lower blood bile acid levels reduce itch mediators, delivering 40% itch relief within 12 weeks in clinical trials [1].
In primary biliary cholangitis (PBC), your immune system damages bile ducts, trapping bile acids in your liver and bloodstream. The GLIMMER trial (2023) showed that linerixibat 40 mg daily reduced serum bile acids by an average of 35–45%, and this drop correlated directly with itch improvement [1][4]. Patients reported meaningful relief by week 4, with maximum benefit by week 12 [1].
Your gut normally reabsorbs 95% of bile acids in the terminal ileum—a recycling loop called enterohepatic circulation. Linerixibat reversibly blocks this recycling, forcing bile acids into stool instead [6]. This shift reduces circulating bile acid levels, which lowers serum autotaxin and other itch-triggering molecules that activate skin nerve endings [4].
The trade-off is increased fecal bile acid loss, which can loosen stools in 20–30% of patients [8]. C4 bile acid metabolite levels (a marker of bile acid synthesis) predict who will experience diarrhea; if your C4 is >300 nmol/L, loose stools are more likely [8]. Most diarrhea is mild and self-limiting by week 8, manageable with dietary fiber or loperamide if needed [5].
Ask your doctor to check your baseline C4 bile acid metabolite before starting linerixibat. If it's elevated, discuss dietary fiber strategies or anti-diarrheal backup. This one lab result helps you predict tolerability and plan your first month [8].